ClinicalTrials.Veeva

Menu

Cold-induced Brown Fat Activation and Hepatic Steatosis

Medical University of Vienna logo

Medical University of Vienna

Status

Enrolling

Conditions

Non-Alcoholic Fatty Liver Disease

Treatments

Other: Cold exposure

Study type

Interventional

Funder types

Other

Identifiers

NCT03811236
1911/2017

Details and patient eligibility

About

In the recent years, research on brown adipose tissue (BAT) revealed that larger amounts as well as higher activity thereof are associated with a favourable metabolic phenotype. Longitudinal studies which applied recurrent cooling sessions demonstrated a high plasticity of BAT which significantly increased in size and activity during these studies. These changes were accompanied by improvements in body fat mass as well as insulin sensitivity. Non-alcoholic fatty liver disease (NAFLD) is estimated to advance to the primary cause of liver cirrhosis and hepatocellular carcinoma in the following years. Besides predisposing genetic and possibly nutritional factors, the insulin resistance syndrome and obesity are the main factors contributing to this excessive hepatic lipid accumulation.

The aim of this study is to investigate whether BAT recruitment via cold-acclimation results in decreased hepatic lipid content in overweight/obese patients with NAFLD.

Enrollment

26 estimated patients

Sex

All

Ages

18 to 50 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • body mass index 28 - 40 kg/m^2
  • hepatic lipid content > 10 %

Exclusion criteria

  • endocrine disease, except treated hypo-/hyperthyroidism and hypertriglyceridemia (<500 mg/dl) and untreated type II diabetes mellitus (fasting glucose < 140 mg/dl)
  • use of beta-blockers, alpha-blockers and rilmenidine
  • chronic kidney disease
  • inflammatory bowel disease
  • active malignant disease
  • autoimmune disease
  • chronic alcohol abuse or alcohol consumption greater than 30g/d for men or 20 g/d for women
  • transferrin saturation > 40%
  • serum alpha-1 antitrypsin < 90 mg/dl
  • serum ceruloplasmin < 20 mg/dl
  • positive serology for autoimmune hepatitis
  • positive hepatitis serology
  • liver cirrhosis
  • portal hypertension
  • pregnancy
  • contraindications for magnetic resonance imaging

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

26 participants in 2 patient groups

Cold exposure
Experimental group
Treatment:
Other: Cold exposure
Room temperature
No Intervention group

Trial contacts and locations

1

Loading...

Central trial contact

Florian Kiefer, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems